Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | TERT | O14746 | 3/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14035674 | 0.79 | CYP1A2 (0.53) | CYP1A2KDM1AKDM4EPOLBLMNA | |
| SCHEMBL17918989 | 0.79 | EGFR (0.55) | KDM1AKDM4EPOLBCASP6NPC1 | |
| SCHEMBL24803121 | 0.78 | EGFR (0.47) | CYP1A2KDM1AKDM4EPOLBCASP6 | |
| SCHEMBL10939039 | 0.78 | KDM1A (0.70) | CYP1A2KDM1AKDM4EPOLBLMNA | |
| SCHEMBL10133371 | 0.78 | NPC1 (0.52) | CYP1A2KDM1AKDM4EPOLBLMNA | |
| SCHEMBL8355880 | 0.78 | NPC1 (0.68) | CYP1A2KDM1AKDM4EPOLBNPC1 | |
| SCHEMBL24894010 | 0.78 | NPC1 (0.63) | CYP1A2KDM1AKDM4EPOLBLMNA | |
| SCHEMBL2175124 | 0.77 | NPC1 (0.67) | CYP1A2KDM1AKDM4EPOLBLMNA | |
| SCHEMBL9676236 | 0.77 | NPC1 (0.51) | CYP1A2KDM1AKDM4EPOLBLMNA | |
| SCHEMBL8902362 | 0.76 | EGFR (0.45) | KDM1APOLBCASP6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400505-A1 | PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF | Bivision Pharmaceuticals, Inc (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-8008324-B2 | Antitumor agents; N-propargyl-N-(2-methyl-6-quinolyl)-[1-(4-chlorobenzyl)indol-3-yl]glyoxylamide | AETERNA ZENTARIS GMBH (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20080153875-A1 | Novel indole derivatives and their use as medicament | AETERNA ZENTARIS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153875-A1 | Novel indole derivatives and their use as medicament | IDO1, TPH1, IDO2 | CYP1A2 192/4885KDM1A 1426/4885KDM4E 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.